Xencor News

Peeling Back The Layers: Exploring Xencor Through Analyst Insights

In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showcasing the evolvi

BenzingaJun 14 14:00 ET

Express News | Raymond James Maintains Strong Buy on Xencor, Lowers Price Target to $40

BenzingaJun 14 11:40 ET

Xencor Is Maintained at Outperform by RBC Capital

Xencor Is Maintained at Outperform by RBC Capital

Dow JonesJun 14 10:20 ET

BMO Capital Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $32

BMO Capital analyst Etzer Darout maintains $Xencor(XNCR.US)$ with a buy rating, and adjusts the target price from $34 to $32.According to TipRanks data, the analyst has a success rate of 58.7% and a t

moomoo NewsJun 14 07:31 ET · Ratings

Express News | Xencor Inc : BMO Cuts Target Price to $32 From $34

ReutersJun 14 06:50 ET

RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating

Xencor (XNCR) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $21 to $50.

MT NewswiresJun 14 06:31 ET

Express News | Xencor Inc : RBC Cuts Target Price to $31 From $32

ReutersJun 14 00:19 ET

Express News | Xencor Inc : Wedbush Cuts Target Price to $34 From $36

ReutersJun 13 10:15 ET

Xencor: J&J's Janssen Termintates Rights to Plamotamab

Xencor on Thursday said Johnson & Johnson's Janssen unit has terminated its rights to the tumor-targeted antibody plamotamab under a collaboration and license agreement the companies inked in 2021.

WSJJun 13 08:29 ET

Express News | Xencor- Janssen Retained Rights to Develop B-Cell Targeting Cd28 Bispecific Antibodies, Including Jnj-9401 (Psma X Cd28), Jnj-1493 (Cd20 X Cd28)

ReutersJun 13 08:07 ET

Express News | Xencor Inc - Has Been Notified That Janssen Will Terminate Its Rights to Plamotamab Under Collaboration and License Agreement

ReutersJun 13 08:06 ET

Express News | Xencor Inc - Will Regain Exclusive Worldwide Rights to Plamotamab, a Cd20 X Cd3 Bispecific T-Cell Engager

ReutersJun 13 08:06 ET

Xencor Regains CD20 X CD3 Bispecific T-Cell Engager

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to

BusinesswireJun 13 08:01 ET

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues

Xencor, Inc.'s (NASDAQ:XNCR) price-to-sales (or "P/S") ratio of 8.3x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies

Simply Wall StJun 7 06:07 ET

Vir Gains on Early Mid-stage Data for Hepatitis Candidate

Seeking AlphaJun 5 08:46 ET

Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo

Seeking AlphaMay 25 10:24 ET

Buy Rating Affirmed for Xencor: Strong Q1 Financials, FDA Approval, and Promising Pipeline Signal Growth Potential

TipRanksMay 14 04:38 ET

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)

TipRanksMay 12 20:20 ET

Decoding 6 Analyst Evaluations For Xencor

6 analysts have shared their evaluations of Xencor (NASDAQ:XNCR) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below offers a condensed view of their r

BenzingaMay 10 15:00 ET

Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates

Yahoo FinanceMay 10 13:45 ET